The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study

Journal of Human Hypertension

Volumn 20, Issue 12, 2006, Pages 937-945

  Shankar, A ^a   Klein, R ^b   Klein, B E K ^b   Nieto, F J ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CAUCASIAN; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG USE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; SYSTOLIC BLOOD PRESSURE; UNITED STATES; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; URBAN POPULATION; URIC ACID; WISCONSIN;

EID: 33751215875     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002095     Document Type: Article

References (52)

1. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275: 457-464.
2. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106.
3. Sanchez-Lozada LG, Tapia E, Santamaria J, vila-Casado C, Soto V, Nepomuceno T et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237-247.
4. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-360.
5. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45: 18-20.
6. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991; 266: 8604-8608.
7. Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997; 89: 577-582.
8. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F991-F997.
9. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
10. Alderman M, Aiyer KJ. Uric acid: Role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20: 369-379.
11. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973; 132: 401-410.
12. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003; 42: 247-252.
13. Brand FN, McGee DL, Kannel WB, Stokes III J, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985; 121: 11-18.
14. Kahn HA, Medalie JH, Neufeld HN, Riss E, Goldbourt U. The incidence of hypertension and associated factors: The Israel ischemic heart disease study. Am Heart J 1972; 84: 171-182.
15. Selby JV, Friedman GD, Quesenberry Jr CP. Precursors of essential hypertension: Pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990; 131: 1017-1027.
16. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 1991; 17: 969-976.
17. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R et al. Serum uric acid and hypertension: The Olivetti Heart Study. J Hum Hypertens 1994; 8: 677-681.
18. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001; 19: 1209-1215.
19. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42: 474-480.
20. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18: 523-530.
21. Alper Jr AB, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: The Bogalusa Heart Study. Hypertension 2005; 45: 34-38.
22. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33.
23. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-391.
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
25. Beebe M, Green G, Pavloski D. CPT Professional 2005: Current Procedural Terminology, Professional Edn. American Medical Association: Atlanta, GA, 2005 625pp.
26. Duffy WB, Senekjian HO, Knight TF, Weinman EJ. Management of asymptomatic hyperuricemia. JAMA 1981; 246: 2215-2216.
27. Klein R, Klein BE, Lee KE. Changes in visual acuity in a population. The Beaver Dam Eye Study. Ophthalmology 1996; 103: 1169-1178.
28. Linton KL, Klein BE, Klein R. The validity of self-reported and surrogate-reported cataract and agerelated macular degeneration in the Beaver Dam Eye Study. Am J Epidemiol 1991; 134: 1438-1446.
29. Fossati P, Prencipe L, Berti G. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem 1980; 26: 227-231.
30. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
31. The Hypertension Detection and Follow-up Program: Hypertension Detection and Follow-up Program Cooperative Group. Prev Med 1976; 5: 207-215.
32. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226.
33. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-751.
34. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562.
35. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-1293.
36. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-281.
37. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004; 66: 1465-1470.
38. Johnson RJ, Rodriguez-Iturbe B, Kang DH, Feig DI, Herrera-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens 2005; 18: 431-440.
39. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928-933.
40. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 2002; 25: 1790-1794.
41. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346: 913-923.
42. Lain KY, Markovic N, Ness RB, Roberts JM. Effect of smoking on uric acid and other metabolic markers throughout normal pregnancy. J Clin Endocrinol Metab 2005; 90: 5743-5746.
43. Niskanen L, Laaksonen DE, Nyyssonen K, Punnonen K, Valkonen VP, Fuentes R et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004; 44: 859-865.
44. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 1976; 295: 573-577.
45. Tuomilehto J, Elo J, Nissinen A. Smoking among patients with malignant hypertension. Br Med J (Clin Res Ed) 1982; 284: 1086.
46. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817-821.
47. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14: 469-477.
48. Liese AD, Mayer-Davis EJ, Chambless LE, Folsom AR, Sharrett AR, Brancati FL et al. Elevated fasting insulin predicts incident hypertension: The ARIC study. Atherosclerosis risk in communities study investigators. J Hypertens 1999; 17: 1169-1177.
49. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study. Arch Intern Med 2004; 164: 1546-1551.
50. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (London) 2004; 1: 10.
51. Lyu LC, Hsu CY, Yeh CY, Lee MS, Huang SH, Chen CL. A case-control study of the association of diet and obesity with gout in Taiwan. Am J Clin Nutr 2003; 78: 690-701.
52. Becker MA, Schumacher Jr HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461.